Literature DB >> 3419597

Does an inhibitory action of levodopa contribute to motor fluctuations?

J G Nutt1, S T Gancher, W R Woodward.   

Abstract

The possibility that levodopa can both acutely improve as well as worsen motor function was investigated in eight fluctuating parkinsonian patients by administering 2-hour infusions of placebo and of levodopa at suprathreshold, threshold, and subthreshold rates when the subjects had been without medication overnight. Plasma levodopa and clinical status were monitored for an hour before, during, and for 3 hours after the infusions. Placebo infusions were associated with a mild deterioration in motor status during the period of monitoring. Subthreshold infusions were associated with greater motor deterioration than were placebo infusions in five of six subjects, but this deterioration did not occur in any specific temporal relation to the infusion. Threshold infusion rates in three subjects produced a transient improvement in motor function followed by deterioration to below the scores during the hour preceding the infusion and then returned to baseline. Suprathreshold rates in seven of the eight subjects were associated with motor improvement for 1/2 to 3 1/2 hours followed by worsening to below baseline for 30 to 90 minutes and then spontaneous improvement to baseline function. These observations suggest that levodopa causes an acute deterioration in motor function following drug-induced improvement. Thus, the nadir of motor function in levodopa-treated patients may not be simply loss of dopaminergic stimulation and return to the untreated state, but may represent an inhibitory effect of levodopa.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3419597     DOI: 10.1212/wnl.38.10.1553

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.

Authors:  M Merello; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

2.  Pharmacokinetics and effects of levodopa in advanced Parkinson's disease.

Authors:  E Bredberg; J Tedroff; S M Aquilonius; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

4.  Diurnal differences in response to oral levodopa.

Authors:  J P Frankel; Z Pirtosek; P A Kempster; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

5.  Comparison of motor response to apomorphine and levodopa in Parkinson's disease.

Authors:  P A Kempster; J P Frankel; G M Stern; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

6.  Responses of rat substantia nigra compacta neurones to L-DOPA.

Authors:  N B Mercuri; P Calabresi; G Bernardi
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

7.  Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa.

Authors:  J G Nutt; W R Woodward; J H Carter; T L Trotman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-04       Impact factor: 10.154

Review 8.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.

Authors:  N Turjanski; W Fernandez; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-07       Impact factor: 10.154

10.  Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.

Authors:  Matthew A Brodsky; Byung S Park; John G Nutt
Journal:  Arch Neurol       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.